To evaluate the clinical utility of the Patient-Derived Organotypic Tumor Spheroids (PDOTS) model in predicting response to combination immunotherapy in advanced hepatocellular carcinoma (HCC), addressing a critical need for personalized treatment strategies.
Key Findings:
The PDOTS model suggested sensitivity to Lenvatinib and Tislelizumab, which was confirmed by the patient's clinical response, highlighting its potential as a predictive tool.
The observed clinical response was concordant with the PDOTS prediction, reinforcing the model's relevance.
The PDOTS model may partially replicate tumor-immune interactions in HCC, offering insights into treatment mechanisms.
Interpretation:
The study provides preliminary evidence that the PDOTS model may be associated with treatment response in advanced HCC, suggesting its potential for personalized immunotherapy selection and its role in shaping future treatment protocols.
Limitations:
The findings are based on a single-case report, limiting generalizability.
Further prospective studies are needed to validate the predictive value of the PDOTS model across diverse patient demographics.
Conclusion:
The PDOTS model shows promise in guiding treatment decisions for advanced HCC, warranting further investigation in larger cohorts to establish its efficacy and impact on clinical practice.
At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, presented positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.
